Novel coronavirus Non Replicating Viral Vector vaccine from Cansino
CanSino Biologics Inc.
Beijing Institute of Biotechnology
Clinical Stage:phase 3
Vaccine platform:Non Replicating Viral Vector
Type of candidate vaccine: Adenovirus Type 5 Vector
Number of doses:1
Route of Administration: IM
Phase 3 report:
Phase 2 report:
Phase 1 report:
There are no reviews yet.
Your email address will not be published. Required fields are marked *
Your review *
Save my name, email, and website in this browser for the next time I comment.